Comment: Pfizer-Seagen clearance, Sanofi-Maze challenge show US FTC carefully selecting theories of harm in pharma sector
The US Federal Trade Commission’s decision not to challenge Pfizer’s proposed $43 billion acquisition of Seagen, but to file a lawsuit seeking to block Sanofi’s licensing deal with Maze, shows that...To view the full article, register now.
Already a subscriber? Click here to view full article